Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.1K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.1K
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

13.9K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
13.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

100 Years of von Willebrand Disease: The Journey to Contemporary Diagnostic Pathways-An Illustrative Case-Based Narrative Review.

Seminars in thrombosis and hemostasis·2026
Same author

2025 Guidelines for direct oral anticoagulants: a practical guidance on the prescription, laboratory testing, peri-operative and bleeding management.

Internal medicine journal·2025
Same author

Laboratory Assessment of Factor VIII Inhibitors: When Is It Required? A Perspective Informed by Local Practice.

Journal of clinical medicine·2025
Same author

Current and emerging therapies as potential treatment for people with von Willebrand disease.

Expert review of hematology·2024
Same author

Ibrutinib plus rituximab and mini-CHOP in older patients with newly diagnosed DLBCL: a phase 2 ALLG study.

Blood advances·2024
Same author

Indeterminate measurable residual disease by multiparameter flow cytometry is associated with an intermediate risk of clinical relapse in adult patients with acute leukaemia.

Pathology·2024

Related Experiment Video

Updated: Feb 24, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

14.4K

The Overall Hemostatic Potential (OHP) Assay.

Jennifer Curnow1,2

  • 1Departments of Clinical and Laboratory Haematology, Sydney Centres for Thrombosis and Haemostasis, Institute of Clinical Pathology and Medical Research, Westmead Hospital, Westmead, NSW, Australia. jennifer.curnow@sydney.edu.au.

Methods in Molecular Biology (Clifton, N.J.)
|August 15, 2017
PubMed
Summary

The overall hemostatic potential (OHP) assay measures blood clotting and breakdown. This simple assay quantifies coagulation and fibrinolysis, aiding in diagnosing complex bleeding disorders.

Keywords:
Clot lysis assayCoagulationFibrin time curveFibrinolysisGlobal assayOHPOverall hemostatic potential

More Related Videos

Hemocompatibility Testing of Blood-Contacting Implants in a Flow Loop Model Mimicking Human Blood Flow
09:41

Hemocompatibility Testing of Blood-Contacting Implants in a Flow Loop Model Mimicking Human Blood Flow

Published on: March 5, 2020

10.2K
A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time
09:38

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time

Published on: February 14, 2017

14.4K

Related Experiment Videos

Last Updated: Feb 24, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

14.4K
Hemocompatibility Testing of Blood-Contacting Implants in a Flow Loop Model Mimicking Human Blood Flow
09:41

Hemocompatibility Testing of Blood-Contacting Implants in a Flow Loop Model Mimicking Human Blood Flow

Published on: March 5, 2020

10.2K
A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time
09:38

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time

Published on: February 14, 2017

14.4K

Area of Science:

  • Biochemistry
  • Hematology
  • Clinical Diagnostics

Background:

  • The hemostatic system involves intricate balances between procoagulant, anticoagulant, and fibrinolytic factors.
  • Current laboratory assays may not fully capture the integrated hemostatic potential.
  • Assessing hypercoagulable states and fibrinolysis abnormalities requires advanced methods.

Purpose of the Study:

  • To introduce and describe the overall hemostatic potential (OHP) assay.
  • To highlight the OHP assay's ability to quantify both coagulation and fibrinolysis.
  • To demonstrate the OHP assay's utility in evaluating complex hemostatic disorders.

Main Methods:

  • The OHP assay utilizes optical density readings to generate a fibrin time curve.
  • It measures the integrated effects of thrombin/tissue factor-mediated fibrin generation and tissue plasminogen activator (tPA)-mediated fibrinolysis.
  • The assay analyzes platelet-poor plasma.

Main Results:

  • OHP assay parameters quantify the overall procoagulant and fibrinolytic potential.
  • It provides insights into the balance between clot formation and breakdown.
  • The assay is capable of identifying abnormalities not detected by routine coagulation tests.

Conclusions:

  • The overall hemostatic potential (OHP) assay offers a comprehensive assessment of hemostasis.
  • It is particularly useful for diagnosing hypercoagulable states and fibrinolysis defects.
  • The OHP assay is technically simple, cost-effective, and suitable for routine laboratory application.